Overview

Safety Study of LiRIS in Interstitial Cystitis (IC) Patients

Status:
Completed
Trial end date:
2011-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is primarily to evaluate the safety and tolerability of two dose levels of an investigational drug-delivery system (LiRIS) in patients who have moderate to severe symptoms of interstitial cystitis.
Phase:
Phase 1
Details
Lead Sponsor:
Allergan
Collaborator:
TARIS Biomedical, Inc.